DUBLIN--(BUSINESS WIRE)--The "Colon Cancer - Pipeline Review, H1 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Colon Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 12, 40, 3, 169, 18 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 3, 43 and 15 molecules, respectively.
Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Colon Cancer - Overview
- Colon Cancer - Therapeutics Development
- Colon Cancer - Therapeutics Assessment
- Colon Cancer - Companies Involved in Therapeutics Development
- Colon Cancer - Drug Profiles
- Colon Cancer - Dormant Projects
- Colon Cancer - Discontinued Products
- Colon Cancer - Product Development Milestones
- Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5nmxtp/colon_cancer?w=4
